Category: Research


Faculty awarded ASC seed grant through Holden Comprehensive Cancer Center

Two early-career scientists have each been awarded a one-year, $30,000 American Cancer Society Institutional Research Grant through Holden Comprehensive Cancer Center at the UI.


NCI-designated cancer centers call for urgent action to get HPV vaccination back on track

Cancers caused by human papillomavirus (HPV) are a significant public health problem in the United States. But these cancers are preventable with HPV vaccination.


Hydrogen peroxide producing drug boosts cancer-killing effect of radiotherapy

Drug simultaneously protects healthy tissue from harmful radiation side-effects.


Holden Comprehensive Cancer Center receives fourth renewal from the National Cancer Institute

University of Iowa Holden Comprehensive Cancer Center has received its fourth renewal as a comprehensive cancer center from the National Cancer Institute (NCI), part of the National Institutes of Health.

Innovation Research

Musculoskeletal Tumor Registry collects QoL data after surgery in sarcoma

Benjamin J. Miller, MD, MS, discusses the creation of the Musculoskeletal Tumor Registry and how it is poised to make progress in the orthopedic oncology field with OncLive.


Work led by team at University of Iowa Holden Comprehensive Cancer Center enables greater access to targeted diagnosis and treatment of rare cancer

People with a rare cancer will have greater access to a drug enabling targeted diagnosis and treatment, thanks to work led by a team of researchers at University of Iowa Health Care’s PET Imaging Center.


Sarcoma outcomes improve at high-volume centers.

Sarcoma patients treated at high-volume medical centers may have higher survival rates than those treated at low-volume centers.


Hawkeyes and Cyclones work side by side in unique cancer research project.

Cancer researchers at two Iowa universities are collaborating on research to address cancer similarities in humans and their companion animals.


Study suggests new approach to treating kids with relapsed cancer.

The study’s findings may provide insight on new approaches or combination therapies to improve other forms of chemotherapy and limit side effects.


Neuroendocrine tumor program earns high European distinction.

The European Neuroendocrine Tumor Center of Excellence designation demonstrates Holden’s full commitment to neuroendocrine tumor care and prevention.